Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2010078331) METHODS FOR SELECTING AN HIV TREATMENT REGIMEN
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2010/078331 International Application No.: PCT/US2009/069694
Publication Date: 08.07.2010 International Filing Date: 29.12.2009
IPC:
C12N 7/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7
Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
Applicants:
PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street Cambridge, MA 02138, US (AllExceptUS)
QIN, Xuebin [US/US]; US (UsOnly)
HU, Weiguo [CA/US]; US (UsOnly)
HALPERIN, Jose, A. [US/US]; US (UsOnly)
Inventors:
QIN, Xuebin; US
HU, Weiguo; US
HALPERIN, Jose, A.; US
Agent:
BIEKER-BRADY, Kristina; Clark & Elbing LLP 101 Federal Street Boston, MA 02110, US
Priority Data:
61/141,45630.12.2008US
Title (EN) METHODS FOR SELECTING AN HIV TREATMENT REGIMEN
(FR) MÉTHODE DE SÉLECTION D'UN RÉGIME DE TRAITEMENT DU VIH
Abstract:
(EN) The invention features methods for selecting an HIV treatment regimen for HIV positive subjects. Such regimens include the administration of CD59 inhibitors including ΪLY domain 4. CD59 activity is associated with a decreased sensitivity to endogenous and exogenous anti-HIV antibodies. Desirably, administration of ILY domain 4 polypeptides is sufficient to inhibit CD59 activity while avoiding the general toxicity associated with full length ILY.
(FR) La présente invention concerne des méthodes de sélection d'un régime de traitement du VIH pour les sujets positifs au VIH. De tels régimes incluent l'administration d'inhibiteurs de CD59 incluant un domaine 4 de ILY. L'activité de CD59 est associée à la diminution de la sensibilité aux anticorps anti-VIH endogènes et exogènes. De préférence, l'administration de polypeptides du domaine 4 de ILY est suffisante pour inhiber l'activité de CD59 en évitant la toxicité généralement associée à l'ILY complète.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)